ArticlebioRxiv : the preprint server for biology2026
EpiExpr: Predicting gene expression using epigenetic data and chromatin interactions.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Decoding gene expression from epigenomic landscapes remains a fundamental challenge in genomics. We introduce EpiExpr, a flexible deep learning framework that predicts gene expression from 1D epigenetic tracks (EpiExpr-1D) and integrates 3D chromatin interactions (EpiExpr-3D) to capture distal regulatory effects. Leveraging residual convolutional networks and graph neural networks, including graph attention and graph transformer models, EpiExpr models both local and long-range regulatory influences. Applied to GM12878 and K562 cells, EpiExpr-1D and 3D improve gene expression prediction relative to reference approaches. Analysis using CRISPRi-FlowFISH validated enhancers confirms that EpiExpr-3D accurately prioritizes regulatory elements, compatible with activity-by-contact scores. Remarkably, EpiExpr achieves performance comparable to DNA sequence-based transformer models without requiring sequence embeddings, offering a computationally efficient alternative. This approach provides a scalable, multi-resolution framework (https://github.com/souryacs/3CExpr) for dissecting the contributions of epigenetic modifications and 3D genome organization to gene regulation, enabling broader application across cell types and experimental settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.